Abstract
Cell-penetrating peptides (CPPs) are short transport peptides with a well-established ability for delivery of bioactive cargoes inside the cells both, in vitro and in vivo. CPPs enter unselectively in a wide variety of cell lines, this is a desirable property for most in vitro applications, however, in vivo e.g. in tumor models, specific targeted accumulation is required. In order to achieve tumor targeting, a known CPP, YTA4, was modified by prolonging it C-terminally with mainly negatively charged amino acids. Additionally, a matrix metalloproteinase-2 cleavage site was introduced between the CPP and the inactivating sequence. This new peptide, named NoPe, is an inactive pro-form of YTA4. It can be selectively cleaved and thereby activated by MMPs. We have conjugated an imaging agent, fluoresceinyl carboxylic acid, and a cytostatic agent methotrexate, to this activable pro-form. NoPe activation was demonstrated in vitro by recombinant MMP-2 cleavage and the cleavage of the attenuating sequence was abolished with MMP-2 specific inhibitor. Furthermore, the fluoresceinyl-NoPe is selectively accumulated in the tumor tissue in MDA-MB-231 tumor bearing mice after intravenous injection. Thus, this strategy proves to be successful for in vivo tumor imaging.
Similar content being viewed by others
Abbreviations
- CPP:
-
Cell-penetrating peptide
- LDH:
-
Lactate dehydrogenase
- MMP:
-
Matrix metalloproteinase
References
Bauvois B (2004) Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23:317–329
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392
Goun EA, Shinde R, Dehnert KW, Adams-Bond A, Wender PA, Contag CH, Franc BL (2006) Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. Bioconjug Chem 17:787–796
Hansen M, Kilk K, Langel Ü (2008) Predicting cell-penetrating peptides. Adv Drug Deliv Rev 60:572–579
Holm T, Johansson H, Lundberg P, Pooga M, Lindgren M, Langel Ü (2006) Studying the uptake of cell-penetrating peptides. Nat Protoc 1:1001–1005
Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101:17867–17872
Karlström A, Undén A (1996) Design of protecting groups for the beta-carboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation. Int J Pept Protein Res 48:305–311
Kastrup B, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbaek K (2008) Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol 80:61–66
Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50:87–100
Kurrikoff K, Suhhorutshenko J, Langel Ü (2012) Cell-penetrating peptides in cancer targeting. In: Kratz F, Senter P, Steinhagen H (eds) Drug delivery in oncology. From basic research to cancer therapy, vol 3. Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim, pp 1189–1217
Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, Krieg T, Mauch C (1999) Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 274:21056–21062
Laakkonen P, Vuorinen K (2010) Homing peptides as targeted delivery vehicles. Integr Biol (Camb) 2:326–337
Lauer JL, Fields CG, Fields GB (1994) Sequence dependence of aspartimide formation during Fmoc solid phase synthesis. Lett Pept Sci 1:197–205
Lindberg S, Copolovici DM, Langel Ü (2011) Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Ther Deliv 2:71–82
Lindgren M, Rosenthal-Aizman K, Saar K, Eiriksdottir E, Jiang Y, Sassian M, Östlund P, Hällbrink M, Langel Ü (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71:416–425
Mäger I, Eiriksdottir E, Langel K, El Andaloussi S, Langel Ü (2010) Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochim Biophys Acta 1798:338–343
Myrberg H, Zhang L, Mäe M, Langel Ü (2008) Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem 19:70–75
Papparella S, Restucci B, Paciello O, Maiolino P (2002) Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. J Comp Pathol 126:271–276
Pipkorn R, Waldeck W, Spring H, Jenne JW, Braun K (2006) Delivery of substances and their target-specific topical activation. Biochim Biophys Acta 1758:606–610
Rutges JP, Kummer JA, Oner FC, Verbout AJ, Castelein RJ, Roestenburg HJ, Dhert WJ, Creemers LB (2008) Increased MMP-2 activity during intervertebral disc degeneration is correlated to MMP-14 levels. J Pathol 214:523–530
Schönherr E, Schaefer L, O’Connell BC, Kresse H (2001) Matrix metalloproteinase expression by endothelial cells in collagen lattices changes during co-culture with fibroblasts and upon induction of decorin expression. J Cell Physiol 187:37–47
Seiki M, Mori H, Kajita M, Uekita T, Itoh Y (2003) Membrane-type 1 matrix metalloproteinase and cell migration. Biochem Soc Symp 70:253–262
Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M (1995) Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 64:355–359
Vivès E, Schmidt J, Pèlegrin A (2008) Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786:126–138
Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG (2011) Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep 26:237–245
Acknowledgments
This work was supported by CePeP AB, Sweden, Cancer Foundation, Sweden, Swedish Research Council VR-NT, Stockholm Centre for Biomembrane Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mäe, M., Rautsi, O., Enbäck, J. et al. Tumour Targeting with Rationally Modified Cell-Penetrating Peptides. Int J Pept Res Ther 18, 361–371 (2012). https://doi.org/10.1007/s10989-012-9312-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-012-9312-1